Post Content
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Revolution Medicines, Inc. (NASDAQ:RVMD) ranks 5th on this list.
Revolution Medicines, Inc. (NASDAQ:RVMD) has featured in the 13F portfolio of Farallon Capital since the first quarter of 2021. Back then, this position comprised 1.6 million shares. Since then, the fund has gradually added to this stake. Filings for the fourth quarter of 2025 show that the fund owned 14.5 million shares in the company, roughly the same as in the third quarter of 2025. Revolution is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers.
Revolution Medicines, Inc. (NASDAQ:RVMD) is turning heads on Wall Street after posting unprecedented data from the Phase 3 RASolute 302 trial of its lead candidate, daraxonrasib. The trial showed a statistically significant overall survival benefit in metastatic pancreatic cancer, a disease that has seen almost no major therapeutic breakthroughs in decades. Hedge funds are positioning ahead of the ASCO Plenary Session in May, where full data will be presented. Investors are rewarding Revolution for its competitive moat strategy as well. Earlier this month, the stock surged after the company sent a cease-and-desist letter to rival Erasca, alleging patent infringement and trade-secret misappropriation related to their own RAS inhibitor. Hedge funds view this aggressive posture as a sign that Revolution intends to protect its multi-billion dollar pan-RAS monopoly, making it a safer long-term bet compared to smaller biotech competitors.
While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 14 Best Defensive Stocks to Invest In Now and 14 Best Low Risk High Growth Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.